Zhifei Bio's pneumonia vaccine achieves positive trial results
Chongqing Zhifei Biological Products (SZSE:300122) reported that its subsidiary, Zhifei Green Bamboo Pharmaceutical, has received the Phase III clinical trial summary report for its 15-valent pneumococcal conjugate vaccine. The vaccine aims to prevent invasive diseases caused by 15 serotypes of Streptococcus pneumoniae. The trial results demonstrate good immunogenicity and safety, achieving all pre-set goals and meeting standards for immunogenicity and safety assessment.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime